An update on Cladribine for relapsing-remitting multiple sclerosis
Pub Med Despite recent progress, currently available therapies for relapsing remitting multiple sclerosis (MS) are only partly effective, and their…
Combo Can Stop Tysabri-related #PML Infection from Worsening, Case Study Shows
FEBRUARY 9, 2018 – BY ALICE MELÃO IN ALEXA, NEWS. A combination of an anti-viral therapy and the anti-depressive mirtazapine…
Stuart Schlossman
The JC Virus and Risks for People with Multiple Sclerosis (MS)
Healthline – Medically reviewed by Deborah Weatherspoon, PhD, RN, CRNA on January 2, 2018 — 12345 What is the JC virus?…
Stuart Schlossman
Aaron Boster, MD Video: I don’t agree with the Escalation Model of treating Multiple Sclerosis
Published on Feb 10, 2018 Aaron Boster, MD : I don’t agree with the Escalation Model of treating Multiple Sclerosis The…
Stuart Schlossman
Mapi Pharma Doses First PPMS Patient in Phase 2 Trial Evaluating GA Depot
February 1, 2018 The Phase 2a trial of GA Depot (glatiramer acetate) for the treatment of primary progressive multiple sclerosis (PPMS) has…
Stuart Schlossman
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
Oct 28, 2017 PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on…
Stuart Schlossman
The History of Ocrevus’ – The Journey from Defiant Idea to Game-Changing Treatment
Information found below was acquired from MS NewsToday Link Twenty years ago, the idea that B-cell depletion could treat multiple…
Stuart Schlossman
Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports
Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse…
Stuart Schlossman
Clomipramine, an Antidepressant, Shows Potential in Treating Progressive MS in Early Study
December 29, 2017 Clomipramine, an approved antidepressant, shows potential in treating people with progressive multiple sclerosis (MS) — a disease…
Stuart Schlossman
Novartis multiple sclerosis therapy Fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1)– In a pivotal Phase III study,…
Stuart Schlossman
